Geron (GERN) Stock Price & Analysis
Score
AI Analysis
SnapshotGeron is a growth-led story right now — Growth 96/100 is the pillar doing the heavy lifting (overall 66/100) in Biotechnology. Under the hood: revenue compounding ~10822% annually over recent years. Street targets still imply ~509% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Geron Corporation (GERN) last printed $0.97. Equity value is $622.98M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $6.16M | $1.06M | $1.07M | $460,000.00 | $253,000.00 | $1.39M | $596,000.00 | $237,000.00 | $76.99M | $183.88M |
About
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.